2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Supportive Care, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Women’s Health, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

6142 Real-world implementation of multidisciplinary recommendations for heavy menstrual bleeding in a combined hematology-gynecology clinic

Parthiv Vipul Sheth, MD, Jenny Y Zhou, MD2
1 University of California San Diego, La Jolla, California, United States
2 University of California San Diego, La Jolla, California, United States

Background:
Women with bleeding disorders and those with thrombotic conditions requiring anticoagulation (AC) experience disproportionately high rates of heavy menstrual bleeding (HMB). Management requires coordinated hematologic and gynecologic care while balancing bleeding and thrombotic risks as well as patient preferences. Combined hematology-gynecology clinics have emerged to address these challenges; however, data describing implementation of multidisciplinary recommendations remain limited. This study describes real-world treatment recommendations and intervention-specific uptake among patients evaluated for HMB in a combined hematology-gynecology clinic.

Methods:
We performed a retrospective chart review of adult patients evaluated for HMB in a combined hematology-gynecology clinic at University of California San Diego from October 2020 to March 2026. Patients without HMB were excluded. Patients were categorized as having bleeding disorders (inherited or acquired), thrombotic disorders (receiving or not receiving AC), or HMB without an underlying bleeding or thrombotic disorder. Treatment recommendations and subsequent implementation were abstracted from the medical record. The primary outcome was implementation of at least one clinic recommendation. Intervention-specific uptake was calculated among patients with known follow-up. Categorical variables were compared using Fisher's exact test.

Results:
Of 111 patients evaluated, 93 with HMB were included: 61 with bleeding disorders (48 inherited, 13 acquired), 28 with thrombotic disorders, of whom 23 (82.1%) were receiving AC (60.9% apixaban, 21.7% rivaroxaban, 17.4% warfarin) and 5 (17.9%) were not, and 4 without an underlying bleeding or thrombotic disorder. Across the cohort, the most frequent treatment recommendations were levonorgestrel intrauterine device (LNG-IUD) placement (51.6%), antifibrinolytic therapy (44.1%), and oral hormonal therapy (40.9%). Among patients with bleeding disorders, antifibrinolytic therapy (72.1%), LNG-IUD (45.9%), and oral hormonal therapy (36.1%) were most commonly recommended. In contrast, LNG-IUD (64.3%) and progestin-only oral hormonal therapy (50.0%) were most commonly recommended for thrombotic disorders, whereas antifibrinolytic therapy was infrequently recommended (7.1%). Antifibrinolytic therapy was recommended significantly more often in bleeding disorders than in thrombotic disorders (p<0.001), whereas recommendation rates for oral hormonal therapy and LNG-IUD did not differ significantly between groups. Combination therapy, defined as a gynecologic intervention (hormonal therapy or procedure) plus an antifibrinolytic, factor replacement, or anticoagulation adjustment, was recommended in 36 patients (38.7%) and was more common among patients with bleeding disorders than those with thrombotic disorders (55.7% vs. 3.6%; p<0.001).

Overall, 71 of 93 patients (76.3%) implemented at least one clinic recommendation, 13 (14.0%) did not, and 9 (9.7%) were lost to follow-up. Among the 84 patients with known follow-up, implementation was 84.5% and was similar between bleeding disorders and thrombotic disorders (84.9% vs. 81.5%; p=0.75). Implementation varied by intervention type, with uptake highest for antifibrinolytic therapy (30/41, 73.2%), followed by oral hormonal therapy (20/37, 54.1%), surgical/procedural management (3/7, 42.9%), and LNG-IUD placement (17/45, 37.8%). Combination therapy was implemented in 14 of 33 patients (42.4%) for whom it was recommended. Intervention-specific uptake did not differ between patients with bleeding and thrombotic disorders.

Conclusions:
A combined hematology-gynecology clinic provided multidisciplinary HMB management across a heterogeneous population of patients with bleeding and thrombotic disorders. Combination therapy was recommended substantially more often for patients with bleeding disorders than those with thrombotic disorders, reflecting diagnosis-specific management approaches. Although overall implementation of recommendations was high, uptake differed by intervention type. Despite being the most frequently recommended intervention, LNG-IUD placement demonstrated relatively low uptake, underscoring the importance of understanding patient preferences and barriers to implementation. Prospective studies are needed to evaluate patient-reported bleeding and hematologic outcomes and identify factors influencing uptake of recommended therapies.

Parthiv Vipul Sheth, MD: No relevant conflicts of interest to declare.